Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial

医学 安慰剂 临床终点 内科学 人口 癌症 外科 随机对照试验 病理 环境卫生 替代医学
作者
Kohei Shitara,Toshihiko Doi,Mikhail Dvorkin,Wasat Mansoor,Hendrik‐Tobias Arkenau,Aliaksandr Prokharau,María Alsina,Michele Ghidini,C. Faustino,В. А. Горбунова,Edvard Zhavrid,Kazuhiro Nishikawa,Ayumu Hosokawa,Şuayib Yalçın,Kazumasa Fujitani,Giordano Beretta,Eric Van Cutsem,Robert Winkler,Lukas Makris,David H. Ilson
出处
期刊:Lancet Oncology [Elsevier BV]
卷期号:19 (11): 1437-1448 被引量:417
标识
DOI:10.1016/s1470-2045(18)30739-3
摘要

Trifluridine/tipiracil showed activity and was well tolerated in a phase 2 study of pretreated patients with advanced gastric cancer done in Japan. We investigated whether the treatment was efficacious compared with placebo in a global population.TAGS was a randomised, double-blind, placebo-controlled, phase 3 trial done in 110 academic hospitals in 17 countries. Patients aged 18 years or older with histologically confirmed, non-resectable, metastatic gastric adenocarcinoma (including adenocarcinoma of the gastroesophageal junction) as defined by the American Joint Committee on Cancer staging classification (7th edition) who had received at least two previous chemotherapy regimens and had experienced radiological disease progression were eligible for inclusion. Patients were randomly assigned (2:1) via dynamic randomisation from a centralised interactive voice-response system to receive either oral trifluridine/tipiracil (35 mg/m2 twice daily on days 1-5 and days 8-12 every 28 days) plus best supportive care or placebo plus best supportive care. Participants were allocated to groups by study-site personnel. Randomisation was stratified by region (Japan vs rest of world), ECOG performance status (0 vs 1), and previous treatment with ramucirumab (yes vs no). Both patients and investigators were masked to treatment allocation. The primary endpoint was overall survival. Efficacy was assessed in the intention-to-treat population and safety in all patients who received at least one dose of treatment. This trial is registered with ClinicalTrials.gov, number NCT02500043. The trial, including follow-up of all participants, has been completed.Between Feb 24, 2016, and Jan 5, 2018, 507 patients were enrolled and randomly assigned, 337 to the trifluridine/tipiracil group and 170 to the placebo group. Median overall survival was 5·7 months (95% CI 4·8-6·2) in the trifluridine/tipiracil group and 3·6 months (3·1-4·1) in the placebo group (hazard ratio 0·69 [95% CI 0·56-0·85]; one-sided p=0·00029, two-sided p=0·00058). Grade 3 or worse adverse events of any cause occurred in 267 (80%) patients in the trifluridine/tipiracil group and 97 (58%) in the placebo group. The most frequent grade 3 or worse adverse events of any cause were neutropenia (n=114 [34%]) and anaemia (n=64 [19%]) in the trifluridine/tipiracil group and abdominal pain (n=15 [9%]) and general deterioration of physical health (n=15 [9%]) in the placebo group. Serious adverse events of any cause were reported in 143 (43%) patients in the trifluridine/tipiracil group and 70 (42%) in the placebo group. One treatment-related death was reported in each group (because of cardiopulmonary arrest in the trifluridine/tipiracil group and because of toxic hepatitis in the placebo group).Trifluridine/tipiracil significantly improved overall survival compared with placebo and was well tolerated in this heavily pretreated population of patients with advanced gastric cancer. Trifluridine/tipiracil could be a new treatment option in this population who represent a high unmet medical need.Taiho Oncology and Taiho Pharmaceutical.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
小吕小吕发布了新的文献求助10
刚刚
刚刚
风中的小蝴蝶完成签到,获得积分10
刚刚
刚刚
1秒前
旷野完成签到,获得积分10
1秒前
1秒前
1秒前
英俊的铭应助hans采纳,获得10
1秒前
mengzhe完成签到,获得积分10
2秒前
同心兆博完成签到,获得积分20
2秒前
敏感凝竹完成签到,获得积分10
3秒前
吴荣菲发布了新的文献求助10
3秒前
3秒前
daorenz发布了新的文献求助30
3秒前
Nancy发布了新的文献求助10
4秒前
5秒前
无限猕猴桃完成签到,获得积分10
5秒前
6秒前
orixero应助相忘于江湖采纳,获得20
6秒前
zzz发布了新的文献求助10
6秒前
11完成签到,获得积分10
8秒前
Ni完成签到,获得积分20
8秒前
chiyudoubao发布了新的文献求助10
8秒前
8秒前
8秒前
9秒前
doudou完成签到,获得积分10
9秒前
萌萌发布了新的文献求助10
10秒前
仰山雪完成签到 ,获得积分10
10秒前
胡占东发布了新的文献求助10
11秒前
11秒前
夹谷蕈完成签到 ,获得积分10
11秒前
深情安青应助Linux2000Pro采纳,获得10
12秒前
12秒前
12秒前
13秒前
06完成签到 ,获得积分10
13秒前
whisper1108完成签到,获得积分10
13秒前
14秒前
高分求助中
Les Mantodea de Guyane Insecta, Polyneoptera 2500
Mobilization, center-periphery structures and nation-building 600
Technologies supporting mass customization of apparel: A pilot project 600
Introduction to Strong Mixing Conditions Volumes 1-3 500
China—Art—Modernity: A Critical Introduction to Chinese Visual Expression from the Beginning of the Twentieth Century to the Present Day 430
Multichannel rotary joints-How they work 400
Tip60 complex regulates eggshell formation and oviposition in the white-backed planthopper, providing effective targets for pest control 400
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 物理 生物化学 纳米技术 计算机科学 化学工程 内科学 复合材料 物理化学 电极 遗传学 量子力学 基因 冶金 催化作用
热门帖子
关注 科研通微信公众号,转发送积分 3796325
求助须知:如何正确求助?哪些是违规求助? 3341295
关于积分的说明 10306023
捐赠科研通 3057851
什么是DOI,文献DOI怎么找? 1677972
邀请新用户注册赠送积分活动 805721
科研通“疑难数据库(出版商)”最低求助积分说明 762775